Drug Sponsors

Catalent invests $20M to expand inhalation capabilities

Monday, January 14, 2013 12:04 PM

Catalent Pharma Solutions, Somerset, N.J.-based developer of solutions and drug delivery technology, is investing $20 million to expand its inhalation drug development, delivery and supply capabilities by enhancing its Inhalation Center of Excellence in Research Triangle Park in North Carolina. The investment will focus on expanding pressurized Metered Dose Inhaler (pMDI) clinical and commercial supply capabilities as well as other enhancements to the facility.

More... »

MorphoSys completes sale of AbD Serotec to Bio-Rad

Friday, January 11, 2013 01:55 PM

MorphoSys, a biotechnology company focusing on fully human antibodies, has completed the sale of its research and diagnostic antibody segment AbD Serotec to Waltham, Mass.-based Bio-Rad Laboratories.

More... »

Saint Luke's Hospital unveils Neuroscience Institute

Friday, January 11, 2013 11:42 AM

Designed to serve as one of the preeminent neuroscience centers in the country, the Saint Luke's Neuroscience Institute (SLNI) tower officially opened January 9 at Saint Luke's Hospital. The new facility, specializing in streamlined care for neurological disorders, offers the Kansas City community and the entire region a dedicated neuroscience hospital, created to lead the way in research, medical advancements, patient outcomes, comfort and quality of care.

More... »

Hikma to acquire the EPCI in Egypt

Friday, January 11, 2013 10:44 AM

Hikma Pharmaceuticals, a multinational pharmaceutical group, has agreed to acquire the Egyptian Company for Pharmaceuticals & Chemical Industries (EPCI) from a consortium of shareholders for an aggregate cash consideration of approximately $22.2 million.

More... »

OPKO Health to acquire Cytochroma

Wednesday, January 9, 2013 03:02 PM

OPKO Health, a multinational pharmaceutical & diagnostics company, has agreed to acquire Cytochroma, a clinical-stage specialty pharmaceutical company.

More... »

Sorrento Therapeutics acquires rights to produce rIVIG

Wednesday, January 9, 2013 02:33 PM

Sorrento Therapeutics, a development-stage biopharmaceutical company, has acquired worldwide rights that will allow for the application of its antibody library technology for the production of recombinant Intravenous immunoglobulins (rIVIG).

More... »

Exela Pharma Sciences to create 38 jobs

Wednesday, January 9, 2013 11:11 AM

Exela Pharma Sciences, a pharmaceutical manufacturer and subsidiary of Exela PharmSci, will expand its facility in Lenoir, N.C.

More... »

Shire to acquire Lotus Tissue Repair

Wednesday, January 9, 2013 09:45 AM

Shire, a global specialty biopharmaceutical company, has signed an agreement to acquire Lotus Tissue Repair, a Cambridge, Mass.-based biotechnology company developing the first and only protein replacement therapy currently being investigated for the treatment of dystrophic epidermolysis bullosa (DEB).

More... »

Questcor Pharmaceuticals to acquire BioVectra

Monday, January 7, 2013 01:18 PM

Questcor Pharmaceuticals, a biopharmaceutical company based in Anaheim Hills, Calif., has signed a definitive agreement to acquire all issued and outstanding shares of BioVectra, a Canadian supplier of contract manufacturing services, for an upfront payment of $50 million.

More... »

Lilly reassumes sole worldwide rights for novel basal insulin analog

Monday, January 7, 2013 10:55 AM

Global pharmaceutical company Eli Lilly and Boehringer Ingelheim, a Germany-based pharmaceutical company, will adjust the scope of their diabetes alliance with respect to LY2605541, Lilly's investigational novel basal insulin analog, with Lilly reassuming sole worldwide development and commercialization rights to LY2605541.

More... »